Comparative effectiveness of pressurized metered-dose inhaler (pMDI) and dry-powdered inhaler (DPI) salmeterol/fluticasone on chronic obstructive pulmonary disease, a single-center study in Hangdong Hospital
Keywords:
COPD, inhaler devices, exacerbations, risk factorsAbstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a major public health concern in Thailand. Standard treatment regimens typically include combinations of inhaled corticosteroids with long-acting beta-adrenergic agonists (ICS/LABA) or long-acting muscarinic antagonists (LAMA). Given the financial constraints of the Universal Coverage Program, evaluating both the clinical efficacy and cost-effectiveness of available therapies is essential. This study aimed to compare the effectiveness and cost of Salmeterol/Fluticasone administered via pressurized metered-dose inhaler (pMDI) versus dry powder inhaler (DPI), and to identify risk factors associated with exacerbations and clinical outcomes.
Materials and Methods: This retrospective cohort study included all COPD patients who regularly visited Hangdong Hospital and received ICS/LABA therapy between January and December 2023. Demographic data, treatment details, and clinical outcomes were reviewed and analyzed. Descriptive statistics were applied, and risk factors were identified using logistic regression. Variables with p < 0.1 in univariate analysis were included in multivariable models, with results reported as adjusted odds ratios and 95% confidence intervals.
Results: Of the 326 patients included, 215 used pMDIs and 111 used DPIs. The DPI group was significantly younger and had a higher proportion of GOLD stage E patients (34.2% vs. 18.6%). Moderate exacerbations were more frequent in the DPI group, primarily due to greater disease severity, while severe exacerbation rates were similar between groups. The strongest predictors of severe exacerbations were a history of more than one prior exacerbation (Adjusted OR 6.70, 95% CI 1.17–38.32, p = 0.033) and LAMA use (Adjusted OR 4.71, 95% CI 2.08–10.70, p < 0.001). Outpatient costs were significantly higher for DPI users, whereas inpatient costs were higher for pMDI users, partly due to increased rates of respiratory failure (25.6% vs. 8.8%, p = 0.018) and mortality (14.6% vs. 0%, p < 0.001).
Conclusion: Neither inhaler type was independently associated with an increased risk of exacerbation. Key risk factors for severe exacerbations included a history of multiple prior exacerbations and LAMA use. DPI use was associated with fewer severe complications and resulted in 13% lower total healthcare costs compared to pMDI use.
References
Department of Disease Control, Ministry of Public Health. Deaths and mortality rate of 5 non-communicable diseases (2017-2021) [Internet]. Nonthaburi: Department of Disease Control; c2562 [updated 2022 Dec 1]. Available from: https://www.ddc.moph.go.th/dncd/news.php?news=39911 [In Thai]
Whittaker H, Rubino A, Müllerová H, Morris T, Varghese P, Xu Y, et al. Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis. 2022;17:427-37. doi: 10.2147/COPD.S346591.
Hurst JR, Han MK, Singh B, Sharma S, Kaur G, de Nigris E, et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022;23(1):213. doi: 10.1186/s12931-022-02123-5.
Amnuaylojaroen T, Parasin N, Limsakul A. Health risk assessment of exposure near-future PM2.5 in Northern Thailand. Air Qual Atmos Health. 2022;15:1963–79.
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE. 2025 GOLD Report global strategy for prevention, diagnosis and management of copd: 2025 report [Internet]. c2025 [cited 2025 Mar 20]. Available from: https://goldcopd.org/2025-gold-report/
Chiangmai Provincial Public Health Office. SMART NCD : Health information reporting system, Chiangmai Provincial Public Health Office [Internet]. Chiang Mai: Chiangmai Provincial Public Health Office; c2024 [cited 2025 Feb 24]. Available from: https://smart-ncd.chiangmaihealth.go.th/web/index.php?r=report/group [In Thai]
Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37(6):1308-31. doi: 10.1183/09031936.00166410.
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588-99. doi: 10.1046/j.1365-2125.2003.01892.x.
Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, et al. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017;124:6-14. doi: 10.1016/j.rmed.2017.01.006.
Darbà J, Ramírez G, Sicras A, Francoli P, Torvinen S, Sánchez-de la Rosa R. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:2335-45. doi: 10.2147/COPD.S90155.
Ram FS, Wright J, Brocklebank D, White JE. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma. BMJ. 2001;323(7318):901-5. doi: 10.1136/bmj.323.7318.901.
Jones R, Martin J, Thomas V, Skinner D, Marshall J, Stagno d'Alcontres M, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. Int J Chron Obstruct Pulmon Dis. 2017;12:2445-54. doi: 10.2147/COPD.S141409.
Wittbrodt ET, Millette LA, Evans KA, Bonafede M, Tkacz J, Ferguson GT. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β2-agonist via dry-powder inhalers and pressurized metered-dose inhalers. Int J Chron Obstruct Pulmon Dis. 2018;14:101-14. doi: 10.2147/COPD.S177213.
Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-71. doi: 10.1378/chest.127.1.335.
Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.
Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, et al. The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med. 2006;100(9):1479-94. doi: 10.1016/j.rmed.2006.01.008.
Sanchis J, Gich I, Pedersen S; Aerosol Drug Management Improvement Team (ADMIT). Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time?. Chest. 2016;150(2):394-406. doi: 10.1016/j.chest.2016.03.041.
Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2):1601794. doi: 10.1183/13993003.01794-2016.
Pothirat C, Chaiwong W, Phetsuk N, Pisalthanapuna S, Chetsadaphan N, Choomuang W. Evaluating inhaler use technique in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;10:1291-8. doi: 10.2147/COPD.S85681.
Molimard M, Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28(3):219-28. doi: 10.1089/jamp.2014.1142.
Khassawneh BY, Al-Ali MK, Alzoubi KH, Batarseh MZ, Al-Safi SA, Sharara AM, et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008;53(3):324-8.
Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration. 2008;75(1):18-25. doi: 10.1159/000109374.
Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V. Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation. Chronic Obstr Pulm Dis. 2017;4(3):217-24. doi: 10.15326/jcopdf.4.3.2017.0183.
Lavorini F, Mannini C, Chellini E, Fontana GA. Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices. Drugs Aging. 2016;33(7):461-73. doi: 10.1007/s40266-016-0377-y.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54. doi: 10.1056/NEJMoa0805800.
Haynes JM, Kaminsky DA, Ruppel GL. The Role of Pulmonary Function Testing in the Diagnosis and Management of COPD. Respir Care. 2023;68(7):889-913. doi: 10.4187/respcare.10757.
Wijnant SRA, De Roos E, Kavousi M, Stricker BH, Terzikhan N, Lahousse L, et al. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J. 2020;55(1):1901217. doi: 10.1183/13993003.01217-2019.
Fortis S, Comellas A, Make BJ, Hersh CP, Bodduluri S, Georgopoulos D, et al; Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2019;16(7):826-35. doi: 10.1513/AnnalsATS.201809-601OC.
Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70-88. doi: 10.1164/rccm.201908-1590ST.
Lowe KE, Regan EA, Anzueto A, Austin E, Austin JHM, Beaty TH, et al. COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. Chronic Obstr Pulm Dis. 2019;6(5):384-99. doi: 10.15326/jcopdf.6.5.2019.0149.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nakornping Hospital
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles that had been published in the journal is copyright of Journal of Nakornping hospital, Chiang Mai.
Contents and comments in the articles in Journal of Nakornping hospital are at owner’s responsibilities that editor team may not totally agree with.
